has been divided into induction chemotherapy and postremission (or consolidation) therapy. Although the first step in controlling the disease is to achieve remission, the patient must also emerge from the induction phase able to tolerate subsequent
Search Results
Acute Myeloid Leukemia
Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret R. O'Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Vijaya Bhatt, Dale Bixby, William Blum, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Steven D. Gore, Aric C. Hall, Patricia Kropf, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Joseph O. Moore, Rebecca Olin, Deniz Peker, Daniel A. Pollyea, Keith Pratz, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Matthew Wieduwilt, Kristina Gregory, and Ndiya Ogba
placebo or midostaurin (50 mg, twice daily on days 8–22) followed by a year of maintenance therapy with placebo or midostaurin (50 mg, twice daily). 28 Patients who received midostaurin with standard induction and consolidation therapy experienced a
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Featured Updates to the NCCN Guidelines
Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Youn H. Kim, Neha Mehta-Shah, Elise A. Olsen, Barbara Pro, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Carlos Torres-Cabala, Ryan Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, and Hema Sundar
Few studies have reported improved survival outcomes with autologous or allogeneic HCT as consolidation therapy for patients with disease in first or second remission. 34 , 42 , 43 Some studies have also reported that graft-versus-lymphoma effect
Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma
Leo I. Gordon
: 310 – 317 . 3. Moskowitz CH Nademanee A Masszi T . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double
Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma
Jean-Luc Harousseau and Philippe Moreau
. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies . Blood 2006 ; 107 : 2633 – 2638 . 18. Moreau P Hullin C Garban F . Tandem autologous
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, and Hema Sundar
demonstrates continued CD20 expression; however; rituximab may be omitted in patients with primary refractory disease. Consolidation therapy with HDT/ASCR (category 1 for patients with CR) ± radiotherapy (RT) is recommended for patients with CR or PR to second
Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Jean-Luc Harousseau
Edited by Kerrin G. Robinson
– 3294 . 23 Spencer A Prince HM Roberts A . Consolidation therapy with thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single ASCT procedure . J Clin Oncol 2009 ; 27 : 1788 – 1793 . 24
PACIFIC: An Ocean of Hope in Patients With Stage III Unresectable Non–Small Cell Lung Cancer
Dipesh Uprety and David E. Marinier
proven. Antonia et al 6 recently reported the results of the phase III PACIFIC trial, which evaluated the role of durvalumab (a selective monoclonal antibody against programmed death-ligand 1 [PD-L1]) as consolidation therapy in patients with stage III
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Rochelle Bagatell, Julie R. Park, Sahaja Acharya, Jennifer Aldrink, Jenna Allison, Elizabeth Alva, Carola Arndt, Daniel Benedetti, Erin Brown, Steve Cho, Alanna Church, Andrew Davidoff, Ami V. Desai, Steven DuBois, Douglas Fair, Joaquim Farinhas, Douglas Harrison, Frederick Huang, Paul Iskander, Susan Kreissman, Margaret Macy, Brian Na, Farzana Pashankar, Praveen Pendyala, Navin Pinto, Stephanie Polites, Raja Rabah, Hiroyuki Shimada, Leonora Slatnick, Elizabeth Sokol, Clare Twist, Kieuhoa Vo, Tanya Watt, Suzanne Wolden, Peter Zage, Ryan Schonfeld, and Lisa Hang
-induction response (partial response or better). 71 However, analyses of randomized trials evaluating different consolidation strategies support a potential role for modern consolidation therapies even in patients with less than a partial response to induction. For
NCCN News
to first-line therapy have the option of being observed or treated with consolidation therapy. Phase III studies have demonstrated that consolidation with radioimmunotherapy (FIT trial) or rituximab (Rituxan, Genentech BioOncology and Biogen Idec
